ROCKVILLE, Md.--(BUSINESS WIRE)--
(NASDAQ: GLYC) today announced that Chief Executive
Officer Rachel King
will provide a company overview at the Jefferies
2017 Global Healthcare Conference in New York City
, on Wednesday, June
, at 2:00 p.m. ET
To access the live webcast and subsequent archived recordings for the
presentation, please visit the GlycoMimetics website at www.glycomimetics.com.
About GlycoMimetics, Inc.
GlycoMimetics is a clinical-stage biotechnology company focused on
cancer and sickle cell disease. GlycoMimetics' most advanced drug
candidate, rivipansel, a pan-selectin antagonist, is being developed for
the treatment of vaso-occlusive crisis in sickle cell disease and is
being evaluated in a Phase 3 clinical trial being conducted by its
strategic collaborator, Pfizer. GlycoMimetics' wholly-owned drug
candidate, GMI-1271, an E-selectin antagonist, is being evaluated in an
ongoing Phase 1/2 clinical trial as a potential treatment for AML and in
a Phase 1 clinical trial in multiple myeloma. The U.S. FDA recently
granted GMI-1271 Breakthrough Therapy designation for treatment of adult
AML patients with relapsed/refractory disease. GlycoMimetics has also
recently initiated a clinical trial with a third drug candidate,
GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is
located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170605005605/en/
Jamie Lacey-Moreira, 410-299-3310
Source: GlycoMimetics, Inc.
News Provided by Acquire Media